PMID: 17170454
Title: A recombinant non pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 HIV 1 Gag elicits cell mediated immunity in mice and decreases HIV 1 replication in human tonsillar tissue following exposure to HIV 1 infection
Abstract: Live-vector human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation that have yielded promising results in pre-clinical testing. In this report, a non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein. Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8(+) T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant L. tarentolae elicited effector memory HIV-1 Gag-specific CD4(+) T lymphocytes and increased antibody titres against HIV-1 Gag. Most importantly, immunization of human tonsillar tissue cultured ex vivo with Gag-expressing L. tarentolae vaccine vector elicited a 75% decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection. These results demonstrated that recombinant L. tarentolae is capable of eliciting effective immune responses in mice and human systems, respectively, and suggest that this novel non-pathogenic recombinant vaccine vector shows excellent promise as a vaccination strategy against HIV-1.
Date: 1970-08-21
Year: 2007
Journal: J. Gen. Virol.
PMID Author: Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B

Media Contacts


Ethel Makila
+254 71 904 3142 



Hester Kuipers
+31 20 521 0343 



Devi Leena Bose
+91 11 4737 6031 


North America

Rose Catlos
+1 212 847 1049